Poland's drug exports to Russia rise 29%

17 June 2007

Poland's drug exports amount to 20% of all the country's exports to Russia, a proportion that is continually increasing, compensating for the Russian embargo on Polish meat products. Last year, Polish drug exports to Russia reached $677.0 million and grew 29%. The most successful sector is the over-the-counter drug business. The Russian drug market is steadily rising, reaching an estimated $10.8-$10.9 billion last year.

In other news, the black market of illegal drugs in Poland is booming. In 2006, police and pharmaceutical inspectors detected 328 instances of illegal or unlicensed drugs. Many of these products were seized at shops, bazaars, private natural medicine practices and other outlets. They are also sold via the Internet, but state control authorities claim to be powerless to inspect on-line distribution channels. Most of these illegal drugs are analgesics, sedatives, anticoagulants, erectile dysfunction and slimming drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight